Form 10-Q Tarsus Pharmaceuticals, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
May 10, 2024 5:24 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $63.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Tarsus reported strong 1Q results with sales of Xdemvy (demodex blepharitis) meaningfully outperforming expectations ($25m vs. $17m cons).... More
